A8724
ADP-ribosyltransferase C3 from Clostridium botulinum
Synonym(s):
Botulinum neurotoxin C3, C3 Exoenzyme, C3 Exotoxin, C3 Transferase
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
Looking for similar products? Visit Product Comparison Guide
Application
ADP-ribosyltransferase C3 from Clostridium botulinum may be used to study cellular signaling and G protein expression .
Biochem/physiol Actions
ADP-ribosyltransferase C3 from Clostridium botulinum ribosylates rho in eukaryotes in the presence of NAD. The ADP-ribosylating exoenzyme forms a single major 25 kDA (approx.) band with SDS electrophoresis. The enzyme labels 21-24 kDa proteins in tissues such as the human platelet membranes.
Ribosylates rho in eukaryotes in the presence of NAD.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
J Michels et al.
Oncogene, 33(30), 3894-3907 (2013-09-17)
Poly(ADP-ribose) polymerase (PARP) inhibitors have raised high expectations for the treatment of multiple malignancies. PARP inhibitors, which can be used as monotherapies or in combination with DNA-damaging agents, are particularly efficient against tumors with defects in DNA repair mechanisms, in
Françoise Dantzer et al.
The FEBS journal, 280(15), 3508-3518 (2013-06-05)
Poly(ADP-ribose) polymerases (PARPs) are enzymes that transfer poly(ADP-ribose) (PAR) groups to target proteins, and thereby affect various nuclear and cytoplasmic processes. The activity of PARP family members, such as PARP1 and PARP2, is tied to cellular signalling pathways, and, through
Jonathan Ledermann et al.
The Lancet. Oncology, 15(8), 852-861 (2014-06-03)
Maintenance monotherapy with the PARP inhibitor olaparib significantly prolonged progression-free survival (PFS) versus placebo in patients with platinum-sensitive recurrent serous ovarian cancer. We aimed to explore the hypothesis that olaparib is most likely to benefit patients with a BRCA mutation.
E Andreas Larsson et al.
Journal of medicinal chemistry, 56(11), 4497-4508 (2013-05-16)
Tankyrases constitute potential drug targets for cancer and myelin-degrading diseases. We have applied a structure- and biophysics-driven fragment-based ligand design strategy to discover a novel family of potent inhibitors for human tankyrases. Biophysical screening based on a thermal shift assay
Jordi Farrés et al.
Blood, 122(1), 44-54 (2013-05-17)
Hematopoietic stem cells self-renew for life to guarantee the continuous supply of all blood cell lineages. Here we show that Poly(ADP-ribose) polymerase-2 (Parp-2) plays an essential role in hematopoietic stem/progenitor cells (HSPC) survival under steady-state conditions and in response to
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service